SARS-CoV2 Data: Real‐World Results of Environmental Surface Testing From a Large Tertiary Cancer Center

In Partnership With:

Patients with hematologic malignancies, which include cancers that affect the blood, bone marrow, and lymph nodes, have demonstrated a higher susceptibility to COVID-19 potentially because of inherent and cancer therapy–related immunosuppression.

Mansi R. Shah, MD

Mansi R. Shah, MD

Patients with hematologic malignancies, which include cancers that affect the blood, bone marrow, and lymph nodes, have demonstrated a higher susceptibility to COVID-19 potentially because of inherent and cancer therapy–related immunosuppression1.

Current evidence suggests that COVID-19–related morbidity and mortality is higher in patients with underlying co-morbidities, male gender, older age, and immunosuppression.2,3 The initial fatality rates reported for patients with cancer who harbored a SARS-CoV-2 infection ranged from 28% in China2 to 26% in North America and Spain.4

With the onset of the unprecedented COVID-19 pandemic, cancer care provision was upended as resource-limited oncology care systems balanced reduction of SARS-CoV-2 exposure with the prioritization of timely cancer diagnostics and treatments. Consensus guidelines that prioritized infection control and re-organization of care were quickly established to limit the negative impact of the pandemic on patients with cancer5,6 whose management involves multiple visits to healthcare facilities for doctor visits, bloodwork, imaging, social work, financial consultations, therapy administration, etc.

Due to the concern of contracting SARS-CoV-2, cancer screening has decreased7 and significantly postponed the identification of new cancer,8 with an estimated increased resultant mortality.9 Compared with the pre-pandemic era, dramatic reductions are observed in the demand for cancer services; this has still not fully recovered. Although COVID-19 is transmitted from person to person through respiratory droplets,10 under laboratory experimental conditions, SARS-CoV-2 was shown to be viable for up to 72 hours; this may be a possible vector of infection for vulnerable patients with cancer.11 There is a potential risk of SARS-CoV-2 spreading via contact with contaminated surfaces and equipment—especially in healthcare settings, creating additional concern for patients with blood cancers.

However, the viability of the virus may differ in real-world clinical environments, promoting the strict use of personal protective equipment (PPE), social distancing, hand hygiene and disinfectant protocols.12 Previously, no studies evaluating SARS-CoV-2 surface contamination in the outpatient or inpatient Hematology and Medical Oncology settings had been published. Thus, in this prospective study, we evaluated the frequency of SARS-CoV-2 on various environmental surfaces in outpatient and inpatient hematology/oncology settings within Rutgers Cancer Institute of New Jersey and Robert Wood Johnson University Hospital, an RWJBarnabas Health facility.13

Environmental sampling was done in high-touch areas in 2 outpatient clinic settings including malignant hematology and medical oncology infusion suites, as well as inpatient areas, which included the leukemia/lymphoma/CAR T-cell unit, and an inpatient unit caring for patients actively infected with COVID-19. Surfaces were sampled on Mondays, Wednesdays, and Fridays from June 17, 2020, through June 29, 2020. Areas included waiting rooms, infusion areas, bathrooms, floors, elevator banks, doors, exam rooms, computer equipment, pneumatic tubing stations, pharmacy areas, and nursing stations. Medical equipment such as intravenous poles, chemotherapy bags, vitals monitor, telemetry stations, and linen carts, in these areas were also swabbed.

A total of 204 samples were collected and characterized as: patient/public areas, staff areas, and medical equipment. In the 2 outpatient clinics and inpatient leukemia/lymphoma/CAR T-cell unit, no SARS-CoV-2 was detected on any swabbed surfaces (0 out of 130). In the inpatient COVID unit, 1 patient/public sample was positive for detection of SARS-CoV-2 in an area where a patient with recent COVID-19 infection was receiving treatment. The overall positive test rate for SARS-CoV-2 across all surfaces in the combined outpatient and inpatient hematology/oncology units was a low 0.5%.

The study revealed extremely low detection of SARS-CoV-2 on environmental surfaces across multiple outpatient and inpatient oncology areas, including an active COVID-19 floor. These data should provide reassurance and highlight the adequacy of established infection prevention and control policies, such as increased use of telemedicine, nursing-directed triage, isolation protocols, and the importance of appropriate personal protective equipment (PPE), social distancing, and disinfection protocols.

Collectively, the results of this study should alleviate concerns of infection transmission for healthcare providers and patients—especially those with blood cancers—when frequenting healthcare facilities to receive their care. We hope to reclaim cancer care when equipped with an improved understanding of SARS-CoV-2 viral transmission dynamics, ongoing infection prevention measures, and accelerated rates of COVID-19 rates of vaccination—especially for patients with cancer.


  1. Dai M, Liu D, Liu M, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter dtudy during the COVID-19 outbreak. Cancer Discov. 2020;10(6):783-791. doi:10.1158/2159-8290.CD-20-0422
  2. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335-337. doi:10.1016/S1470-2045(20)30096-6
  3. Lee LY, Cazier J-B, Angelis V, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020;395(10241):1919-1926. doi:10.1016/S0140-6736(20)31173-9
  4. Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395(10241):1907-1918. doi:10.1016/S0140-6736(20)31187-9
  5. Al-Shamsi HO, Alhazzani W, Alhuraiji A, et al. A practical approach to the management of cancer patients during the novel coronavirus disease 2019 (COVID-19) pandemic: an International Collaborative Group. Oncologist. 2020;25(6):e936-e945. doi:10.1634/theoncologist.2020-0213
  6. Curigliano G, Banerjee S, Cervantes A, et al. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. Ann Oncol. 2020;31(10):1320-1335. doi:10.1016/j.annonc.2020.07.010
  7. Patt D, Gordan L, Diaz M, et al. Impact of COVID-19 on cancer care: how the pandemic Is delaying cancer diagnosis and treatment for American seniors. JCO Clin Cancer Inform. 2020(4):1059-1071. doi:10.1200/CCI.20.00134
  8. Kaufman HW, Chen Z, Niles J, et al. Changes in the number of US patients with newly identified cancer before and during the coronavirus disease 2019 (COVID-19) pandemic. JAMA Netw Open. 2020;3(8):e2017267. doi:10.1001/jamanetworkopen.2020.17267
  9. Lai AG, Pasea L, Banerjee A, et al. Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort study. BMJ Open. 2020;10(11):e043828. doi:10.1136/bmjopen-2020-043828
  10. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020;382(12):1177-1179. doi:10.1056/NEJMc2001737
  11. Van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med. 2020;382(16):1564-1567. doi:10.1056/NEJMc2004973
  12. Chu DK, Akl EA, Duda S, Solo K, et al. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. Lancet. 2020;395(10242):1973-1987. doi:10.1016/S0140-6736(20)31142-9
  13. Shah MR, Jan I, Johns J, et al. SARS-CoV-2 nosocomial infection: Real-world results of environmental surface testing from a large tertiary cancer center. Cancer. 2021;127(11):1926-1932. doi:10.1002/cncr.33453

Mansi R. Shah, MD, is a hematologist/oncologist and assistant professor of medicine in the Division of Blood Disorders at Rutgers Cancer Institute of New Jersey and Robert Wood Johnson Medical School.

Related Videos
David D'Ambrosio, MD
Experts on mantle cell lymphoma
M. Michele Blackwood, MD, FACS
Experts on mantle cell lymphoma
Experts on mantle cell lymphoma
Prateek Gulhati, MD, PhD
Sanjay Goel, MD, MS
Experts on mantle cell lymphoma
Experts on mantle cell lymphoma
Experts on mantle cell lymphoma
Related Content